PRISM PHARMA CO LTD has a total of 71 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are BEIJING KONRUNS PHARMACEUTICAL CO LTD, DONELLO JOHN E and SPERO TRINEM INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 12 | |
#2 | United States | 11 | |
#3 | Australia | 8 | |
#4 | Canada | 8 | |
#5 | Philippines | 6 | |
#6 | Israel | 5 | |
#7 | China | 4 | |
#8 | Republic of Korea | 4 | |
#9 | Mexico | 3 | |
#10 | Singapore | 3 | |
#11 | WIPO (World Intellectual Property Organization) | 3 | |
#12 | Hong Kong | 2 | |
#13 | Hungary | 1 | |
#14 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Biotechnology |
# | Name | Total Patents |
---|---|---|
#1 | Odagami Takenao | 57 |
#2 | Kouji Hiroyuki | 54 |
#3 | Sugaya Yukiko | 15 |
#4 | Kushida Ikuo | 13 |
#5 | Nagai Mitsuo | 8 |
#6 | Isomura Minetaka | 7 |
#7 | Kosaka Yuki | 7 |
#8 | Takenao Odagami | 5 |
#9 | Kohara Michinori | 5 |
#10 | Hori Yusaku | 5 |
Publication | Filing date | Title |
---|---|---|
AU2014371152A1 | Crystal (1) of pyrazino[2,1-c][1,2,4]triazine compound | |
US2016318938A1 | CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND | |
CN105829331A | Method of producing pyrazino[2,1-c][1,2,4]triazine compound | |
US2015306115A1 | Prevention or treatment agent for hepatic fibrosis | |
WO2014088106A1 | Prophylactic or therapeutic agent for fibromyalgia | |
US2015284393A1 | Methods for treating eye disorders | |
EP2908821A1 | Treatment of viral and infectious diseases using an inhibitor of cbp/catenin | |
CA2889017A1 | Treatment of scleroderma using an inhibitor of cbp/catenin | |
EP2908820A1 | Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin | |
AU2013332733A1 | Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of CBP/catenin | |
EP2678341A1 | Alpha helix mimetics and methods relating thereto |